VIR · Vir Biotechnology, Inc.

The shares subject to the stock option vest and become exercisable in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

The RSUs will vest in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders.

1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027, and the remaining shares will vest and become exercisable in 24 equal monthly installments thereafter.

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest in two equal annual installments thereafter.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.

Includes 379 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025.

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

The RSUs will vest in full on May 27, 2027.

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

The RSUs will vest in full on May 27, 2027.

The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

The RSUs will vest in full on May 27, 2027.

The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

The RSUs will vest in full on May 27, 2027.

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

The RSUs will vest in full on May 27, 2027.

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

The RSUs will vest in full on May 27, 2027.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Transfer without consideration for tax and estate planning purposes.

Transfer without consideration for tax and estate planning purposes.

The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.87 to $9.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.

Transfer without consideration for estate planning purposes.

The shares are held in the name of the O'Byrne Family Trust, of which the Reporting Person and his spouse are Trustees.

Transfer without consideration for estate planning purposes.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.97 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.97 to $9.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2025.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.

Shares vested and became exercisable in 36 equal monthly installments from October 5, 2017.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.23 to $10.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person.

Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.v

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

Includes 637 shares of common stock acquired by the Reporting Person on November 28, 2025, pursuant to an employee stock purchase program.

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter.

Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.

25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter.

25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter.